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While the majority of patients with
cancer treated with chemotherapy ini-
tially respond to treatment, a sub-group
of patients either do not respond or
eventually stop responding to the ther-
apy in a phenomenon known as tumor
cell resistance. Evidence of many dif-
ferent mechanisms of resistance have
been reported in the literature, and it
remains a great challenge to delineate
the pathways involved, and subsequently
develop therapies to combat and over-
come chemotherapy resistance. It is only
in the understanding of the mechanisms
of tumor cell resistance to cytotoxic drug-
induced apoptosis at the molecular and
biochemical levels that will allow the
development of drugs that target the
resistance factors.
Dr. Benjamin Bonavida is well-
qualified to edit this book given his
expertise as he has years of investigation,
and well over 100 publications devoted to
understanding tumor cell resistance. Dr.
Bonavida has assembled a stellar cast of
contributing authors that are clearly lead-
ers in this field of study. The book, while
quite comprehensive, is not designed to,
nor does it attempt to cover the entire field
of drug resistance. The focus of the book is
to highlight specific mechanisms of cancer
drug resistance and review or propose new
treatments targeting each of these mecha-
nisms. The contributing authors of the 12
chapters provide reviews of widely studied
aspects of cancer drug resistance, present
the latest findings, and offer speculative
targets for novel drug development. Both
tissue specific mechanisms/interventions
and targets common to many cancers
are included. The practice of single agent
administration and the use of sensitizing
drugs synergized with other therapies are
also discussed. A brief overview of some
of the chapters contained in the book
follows.
The first chapter may be the most
important one for readers that are not
already familiar with cancer drug resis-
tance. It gives an excellent overview of
the phenomenon of multidrug resistance
(MDR) by the overexpression of the
ATP-binding Cassette (ABC) drug trans-
porters. The chapter details the struc-
ture and function, substrate specificity,
and the polymorphic effects on the
three most important ABC genes. Small
molecule targeted therapies and natu-
ral products as modulators (enhanced by
well-referenced tables) are reviewed. This
chapter is followed by a review that pro-
vides details on the role of pH changes
that alter physical properties of the cell
membrane and MDR functions. The
remaining chapters each review impor-
tant mechanisms and pathways that con-
tribute to chemotherapy resistance and
the treatment strategies to overcome this
phenomenon.
An interesting chapter worth mention-
ing reviews what is currently understood
about “collateral sensitivity,” or hyper-
sensitivity to otherwise drug-resistant
cells. This is a lesser-known multiple
mechanism process in drug resistance,
and a possible novel treatment strategy.
The challenges of optimizing combination
therapies, cross-resistance and hypersen-
sitivity in multidrug-resistant cells are
reviewed in detail. This chapter con-
tains an especially helpful table describing
collateral sensitivity in drug-resistant
tumors broken down by currently used cell
lines.
The Raf/MEK/ERK signaling pathways
are often aberrantly activated in cancer
and the description of the mechanisms of
Raf inhibitor resistance and therapies to
target this are discussed in two compre-
hensive chapters. The need for, and appli-
cation of, combination therapies designed
to co-target multiple aspects of signaling
pathways is presented with an emphasis on
personalized medicine. B-Raf as a target
for anti-cancer agents and novel therapeu-
tic strategies are reviewed.
In one of several chapters that focuses
on a tissue specific cancer, the role of
β1 integrins and resistance to lung can-
cer is discussed. This chapter highlights the
importance of the β1 integrin-extracellular
matrix signaling in tumorigenesis and
subsequent drug resistance. The authors
describe ongoing efforts to target the β1
integrin as a potential breakthrough in the
successful treatment of lung cancers. The
aldo-keto reductase (AKR) genes as tar-
gets for chemoresistance in colon cancer
are discussed in a separate chapter. Current
literature focusing on expression profiles
is reviewed and the accompanying figures
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of the important metabolic pathways are
excellent.
Many anticancer agents induce Reactive
Oxygen Species (ROS) that triggers apop-
tosis resulting in cancer cell death. A thor-
ough chapter reviews the ROS molecular
mechanism. The treatment approach to
identify targets for elevating ROS levels as
way of sensitizing drug-resistant cells is
also discussed in detail. Well-written and
referenced chapters that review the role of
apoptosis, DNA repair and signal trans-
duction pathways, TRAIL-apoptotic path-
way, and cancer stem cells in resistance to
cytotoxic drugs are also included in the
book.
Overcoming cancer drug resistance has
become a priority in the treatment of
many types of cancer with drug-resistant
cells becoming harder to kill even with
the arrival of new cytotoxic drugs. The
field is complicated due to the wide array
of pathways and mechanisms involved.
In conclusion, this well-organized book
provides the reader with an excellent
overview of the field of cancer drug
resistance. The test is informative and
comprehensive complemented by exten-
sive references and helpful schema that
make this book a valuable resource for stu-
dents, those new to the field, and veteran
investigators.
Conflict of Interest Statement: The author declares
that the research was conducted in the absence
of any commercial or financial relationships that
could be construed as a potential conflict of
interest.
Received: 09 October 2014; accepted: 06 December 2014;
published online: 23 December 2014.
Citation: Price DK (2014) Combating and overcoming
drug resistance in cancer. Front. Pharmacol. 5:285. doi:
10.3389/fphar.2014.00285
This article was submitted to Pharmacology of Anti-
Cancer Drugs, a section of the journal Frontiers in
Pharmacology.
Copyright © 2014 Price. This is an open-access
article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are
credited and that the original publication in this
journal is cited, in accordance with accepted aca-
demic practice. No use, distribution or reproduc-
tion is permitted which does not comply with these
terms.
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs December 2014 | Volume 5 | Article 285 | 2
